Biosearch Technologies Signs Exclusive License for Single Molecule FISH Technologies from UMDNJ

NOVATO, CA (Thursday, August 5, 2010) – Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has licensed exclusively from the University of Medicine and Dentistry of New Jersey (UMDNJ) a Single Molecule Fluorescent in-situ hybridization technology based on detection of RNA. Biosearch owns the exclusive rights to manufacture, catalogue and sell validated RNA FISH probes, assays and kits into the Research, Applied Markets and IVD fields under the UMDNJ technologies and patent applications.

Marc Beal, Director of Corporate Development at Biosearch Technologies, comments, “Biosearch’s excellence in fluorescence and fluorescent oligonucleotide manufacturing combined with the exclusive licensing of the UMDNJ RNA FISH technologies and patent applications will allow Biosearch to quickly penetrate the marketplace with both assays and kits. As the inventor and patent holder of the CAL Fluor® and Quasar® dye technologies, Biosearch will offer single and multiplexing application options for Research, Applied and IVD medical device markets as well as web-based design through”

"We are very excited to work with Biosearch Technologies to commercialize this technology," says Arjun Raj, co-inventor of the single molecule FISH technology. "We have already seen widespread interest in applying this RNA FISH technique to directly quantify absolute numbers of RNA in a variety of contexts, and Biosearch has exactly the right expertise to put this technology in the hands of researchers and clinicians everywhere." Vincent Smeraglia, Director of the Office of Patents & Licensing, UMDNJ stated, “We are pleased to have Biosearch Technologies as our licensing partner for this novel and exciting technology. We have no doubt that this partnership will result in innovative products that will serve the greater good of the research community and in the end, the public at large.”

About UMDNJ and UMDNJ’s Office of Patents & Licensing.

The University of Medicine and Dentistry of New Jersey (UMDNJ) is the nation's largest free-standing public health sciences university with more than 6,000 students attending the state's three medical schools, its only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and its only school of public health on five campuses. Annually, there are more than two million patient visits at UMDNJ facilities and faculty practices at campuses in Newark, New Brunswick/Piscataway, Scotch Plains, Camden and Stratford. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, which provides a continuum of healthcare services with multiple locations throughout the state. UMDNJ’s Office of Patents & Licensing is the entity responsible for commercialization of UMDNJ’s intellectual property. The office works in partnership with UMDNJ faculty to identify, develop and commercialize most promising academic discoveries.

For additional information about UMDNJ please visit

About Biosearch Technologies, Inc.

Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications.

In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 3003009025), and as such, its contract manufacturing processes conform to all applicable GMP requirements per 21 CFR Part 820. Biosearch markets include pharmaceutical, in-vitro diagnostic, biotech, ag/bio, environmental and food testing, public health, and biodefense sectors.

For additional information about Biosearch Technologies, Inc., contact or visit